Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Biohaven Pharmaceutical files to sell 115,836 shares of common stock for holders  17:03
03/05/21
03/05
17:03
03/05/21
17:03
BHVN

Biohaven Pharmaceutical

$84.03 /

+6.29 (+8.09%)

 
ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$84.03 /

+6.29 (+8.09%)

BHVN Biohaven Pharmaceutical
$84.03 /

+6.29 (+8.09%)

03/02/21 Mizuho
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho
03/01/21 Piper Sandler
Biohaven price target raised to $110 from $90 at Piper Sandler
01/25/21 Piper Sandler
Piper recommends buying Biohaven Pharmaceutical shares at current levels
01/19/21 Canaccord
Biohaven Pharmaceutical price target lowered to $101 from $110 at Canaccord
BHVN Biohaven Pharmaceutical
$84.03 /

+6.29 (+8.09%)

Tuesday
Recommendations
Axsome Therapeutics price target lowered to $118 from $120 at Mizuho » 06:49
03/02/21
03/02
06:49
03/02/21
06:49
AXSM

Axsome Therapeutics

/

+

Mizuho analyst Vamil…

Mizuho analyst Vamil Divan lowered the firm's price target on Axsome Therapeutics to $118 from $120 and keeps a Buy rating on the shares following the company's Q4 results. The analyst expects AXS-05 to obtain a Priority Review, and expects the stock to rise as investors come to appreciate AXS-05's potential.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
/

+

AXSM Axsome Therapeutics
/

+

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
12/15/20 Mizuho
Axsome Therapeutics initiated with a Buy at Mizuho
12/03/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $161 from $131 at Cantor Fitzgerald
AXSM Axsome Therapeutics
/

+

AXSM Axsome Therapeutics
/

+

Recommendations
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho » 06:48
03/02/21
03/02
06:48
03/02/21
06:48
BHVN

Biohaven Pharmaceutical

$86.74 /

+1.64 (+1.93%)

Mizuho analyst Vamil…

Mizuho analyst Vamil Divan raised the firm's price target on Biohaven Pharmaceutical to $103 from $93 and keeps a Buy rating on the shares following the company's :strong" Q4 results.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$86.74 /

+1.64 (+1.93%)

BHVN Biohaven Pharmaceutical
$86.74 /

+1.64 (+1.93%)

03/01/21 Piper Sandler
Biohaven price target raised to $110 from $90 at Piper Sandler
01/25/21 Piper Sandler
Piper recommends buying Biohaven Pharmaceutical shares at current levels
01/19/21 Canaccord
Biohaven Pharmaceutical price target lowered to $101 from $110 at Canaccord
01/19/21 Mizuho
Biohaven Pharmaceutical price target lowered to $93 from $100 at Mizuho
BHVN Biohaven Pharmaceutical
$86.74 /

+1.64 (+1.93%)

Over a week ago
Recommendations
Biohaven price target raised to $110 from $90 at Piper Sandler » 12:08
03/01/21
03/01
12:08
03/01/21
12:08
BHVN

Biohaven Pharmaceutical

$86.20 /

+1.1 (+1.29%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren raised the firm's price target on Biohaven Pharmaceutical to $110 from $90 and keeps an Overweight rating on the shares following the company's Q4 results. "By anyone's standards, Biohaven's launch of Nurtec over the past year has been extremely effective," Van Buren tells investors in a research note. With 89% commercial coverage, leads in new and productive prescribers, and a likely Q2 prevention approval, Biohaven might be able to attain a leading share against competitor Ubrelvy by end of the year, says the analyst.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$86.20 /

+1.1 (+1.29%)

BHVN Biohaven Pharmaceutical
$86.20 /

+1.1 (+1.29%)

01/25/21 Piper Sandler
Piper recommends buying Biohaven Pharmaceutical shares at current levels
01/19/21 Canaccord
Biohaven Pharmaceutical price target lowered to $101 from $110 at Canaccord
01/19/21 Mizuho
Biohaven Pharmaceutical price target lowered to $93 from $100 at Mizuho
01/19/21 H.C. Wainwright
Biohaven price target lowered to $111 from $121 at H.C. Wainwright
BHVN Biohaven Pharmaceutical
$86.20 /

+1.1 (+1.29%)

Conference/Events
Cowen to hold a virtual conference » 09:07
03/01/21
03/01
09:07
03/01/21
09:07
QGEN

Qiagen

$50.02 /

-0.33 (-0.66%)

, SLN

Silence Therapeutics

$28.01 /

+ (+0.00%)

, BIIB

Biogen

$272.68 /

-4.95 (-1.78%)

, AXSM

Axsome Therapeutics

$67.52 /

-1.04 (-1.52%)

, GBT

Global Blood Therapeutics

$42.60 /

-0.885 (-2.04%)

, OCUL

Ocular Therapeutix

$18.40 /

+0.27 (+1.49%)

, ACAD

Acadia

$49.00 /

+1.605 (+3.39%)

, PACB

Pacific Biosciences

$30.57 /

-0.59 (-1.89%)

, ZTS

Zoetis

$155.41 /

-1.14 (-0.73%)

, QTNT

Quotient

$4.49 /

-0.06 (-1.32%)

, DVAX

Dynavax

$8.75 /

+0.595 (+7.30%)

, OTRK

Ontrak

$59.13 /

-3.3 (-5.29%)

, ARQT

Arcutis Biotherapeutics

$34.11 /

+0.01 (+0.03%)

, PFE

Pfizer

$33.49 /

-0.335 (-0.99%)

, BLFS

BioLife Solutions

$39.29 /

+0.07 (+0.18%)

, CHRS

Coherus Biosciences

$16.22 /

+0.97 (+6.36%)

, SAGE

Sage Therapeutics

$85.02 /

+1.45 (+1.74%)

, CERS

Cerus

$6.14 /

-0.325 (-5.03%)

, EXEL

Exelixis

$21.70 /

-0.26 (-1.18%)

, ALNY

Alnylam

$147.94 /

+1.4 (+0.96%)

41st Annual Healthcare…

41st Annual Healthcare Virtual Conference will be held on March 1-4 beginning at 9:10 am on March 1. Webcast Link

ShowHide Related Items >><<
ZTS Zoetis
$155.41 /

-1.14 (-0.73%)

SLN Silence Therapeutics
$28.01 /

+ (+0.00%)

SAGE Sage Therapeutics
$85.02 /

+1.45 (+1.74%)

QTNT Quotient
$4.49 /

-0.06 (-1.32%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

OTRK Ontrak
$59.13 /

-3.3 (-5.29%)

OCUL Ocular Therapeutix
$18.40 /

+0.27 (+1.49%)

GBT Global Blood Therapeutics
$42.60 /

-0.885 (-2.04%)

EXEL Exelixis
$21.70 /

-0.26 (-1.18%)

DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

CHRS Coherus Biosciences
$16.22 /

+0.97 (+6.36%)

CERS Cerus
$6.14 /

-0.325 (-5.03%)

BLFS BioLife Solutions
$39.29 /

+0.07 (+0.18%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

ALNY Alnylam
$147.94 /

+1.4 (+0.96%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
SLN Silence Therapeutics
$28.01 /

+ (+0.00%)

11/18/20 BTIG
Silence Therapeutics initiated with a Buy at BTIG
BIIB Biogen
$272.68 /

-4.95 (-1.78%)

02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
02/08/21 Citi
Expert sees Biogen aducanumab approval 50/50 at best, says Citi
02/04/21 SVB Leerink
Biogen price target lowered to $380 from $430 at SVB Leerink
02/04/21 Credit Suisse
Biogen price target lowered to $338 from $350 at Credit Suisse
AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
12/15/20 Mizuho
Axsome Therapeutics initiated with a Buy at Mizuho
12/03/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $161 from $131 at Cantor Fitzgerald
GBT Global Blood Therapeutics
$42.60 /

-0.885 (-2.04%)

02/25/21 William Blair
Global Blood Therapeutics downgraded to Market Perform at William Blair
01/27/21 Oppenheimer
Global Blood Therapeutics' MAA accepted ahead of schedule, says Oppenheimer
01/20/21 Piper Sandler
Global Blood downgraded to Neutral from Overweight at Piper Sandler
12/15/20 H.C. Wainwright
Global Blood Therapeutics assumed with a Buy at H.C. Wainwright
OCUL Ocular Therapeutix
$18.40 /

+0.27 (+1.49%)

02/12/21 Piper Sandler
Ocular Therapeutix to update on OTX-TKI's Phase I wAMD, says Piper Sandler
12/30/20 JMP Securities
Ocular Therapeutix price target raised to $30 from $20 at JMP Securities
12/28/20
Fly Intel: Top five analyst calls
12/28/20 H.C. Wainwright
Ocular Therapeutix downgraded to Neutral from Buy at H.C. Wainwright
ACAD Acadia
$49.00 /

+1.605 (+3.39%)

02/25/21 Mizuho
Acadia price target raised to $70 from $69 at Mizuho
12/29/20 Cantor Fitzgerald
Acadia price target raised to $70 from $61 at Cantor Fitzgerald
12/15/20 Mizuho
Acadia initiated with a Buy at Mizuho
11/16/20 Raymond James
Acadia upgraded to Strong Buy from Outperform at Raymond James
PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

02/11/21 Cantor Fitzgerald
Pacific Biosciences price target raised to $62 from $45 at Cantor Fitzgerald
02/11/21 Piper Sandler
Pacific Biosciences upgraded to Overweight from Neutral at Piper Sandler
01/15/21 Piper Sandler
Pacific Biosciences price target raised to $20 from $12 at Piper Sandler
01/12/21 Cantor Fitzgerald
Pacific Biosciences price target raised to $45 from $25 at Cantor Fitzgerald
ZTS Zoetis
$155.41 /

-1.14 (-0.73%)

02/17/21 Credit Suisse
Zoetis price target raised to $203 from $197 at Credit Suisse
11/12/20 Truist
Zoetis price target raised to $170 from $160 at Truist
11/06/20 Barclays
Zoetis price target raised to $189 from $175 at Barclays
09/21/20 Atlantic Equities
Zoetis initiated with an Overweight at Atlantic Equities
QTNT Quotient
$4.49 /

-0.06 (-1.32%)

05/18/20 Cowen
Quotient partner update suggests progress on antibody front, says Cowen
DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

02/08/21 Evercore ISI
Dynavax had 'big vaccine update week,' says Evercore ISI
02/01/21 Cowen
Dynavax undervalued for potential of Heplisav and COVID vaccine, says Cowen
02/01/21 H.C. Wainwright
Dynavax price target raised to $15 from $14 at H.C. Wainwright
11/06/20 H.C. Wainwright
Dynavax price target raised to $14 from $12 at H.C. Wainwright
OTRK Ontrak
$59.13 /

-3.3 (-5.29%)

01/05/21 Benchmark
GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
01/04/21 B. Riley Securities
Ontrak price target raised to $110 from $100 at B. Riley Securities
11/18/20 B. Riley Securities
Ontrak initiated with a Buy at B. Riley Securities
10/02/20 Canaccord
Ontrak analysis points to significant upside for shares, says Canaccord
ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

02/02/21 Truist
Arcutis Biotherapeutics price target raised to $48 from $38 at Truist
02/01/21 Cowen
Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen
01/28/21 JonesTrading
Arcutis Biotherapeutics initiated with a Buy at JonesTrading
11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
PFE Pfizer
$33.49 /

-0.335 (-0.99%)

02/23/21 B. Riley Securities
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
BLFS BioLife Solutions
$39.29 /

+0.07 (+0.18%)

12/28/20 Northland
BioLife Solutions price target raised to $55 from $35 at Northland
11/09/20 KeyBanc
BioLife Solutions initiated with an Overweight at KeyBanc
10/19/20 B. Riley Securities
BioLife Solutions price target raised to $35.50 from $30 at B. Riley Securities
09/23/20 B. Riley Securities
BioLife Solutions price target raised to $30 from $25.50 at B. Riley FBR
CHRS Coherus Biosciences
$16.22 /

+0.97 (+6.36%)

02/25/21 Citi
Coherus Biosciences price target lowered to $27 from $30 at Citi
02/25/21 H.C. Wainwright
Coherus Biosciences price target lowered to $29 from $33 at H.C. Wainwright
11/19/20 Mizuho
Coherus Biosciences price target lowered to $30 from $35 at Mizuho
08/21/20 Mizuho
Express Scripts exclusion does not impact Coherus, says Mizuho
SAGE Sage Therapeutics
$85.02 /

+1.45 (+1.74%)

02/26/21 Mizuho
Sage Therapeutics downgraded to Neutral from Buy at Mizuho
02/25/21 Oppenheimer
Sage Therapeutics price target raised to $102 from $90 at Oppenheimer
02/25/21 H.C. Wainwright
Sage Therapeutics price target raised to $86 from $74 at H.C. Wainwright
02/24/21 Stifel
Stifel cuts Sage target to $121, reiterates Buy after quarterly results
CERS Cerus
$6.14 /

-0.325 (-5.03%)

11/30/20 Cowen
Value proposition for Cerus' Intercept cryo 'clear,' says Cowen
10/07/20 BTIG
Cerus assumed with a Buy at BTIG
08/19/20 Stifel
Cerus story about platelets, not convalescent plasma, says Stifel
08/10/20 Cowen
Cerus multi-layered sales growth trajectory 'convincing,' says Cowen
EXEL Exelixis
$21.70 /

-0.26 (-1.18%)

02/15/21 Piper Sandler
Exelixis price target raised to $36 from $33 at Piper Sandler
01/25/21 Piper Sandler
Piper says Exelixis could have 'blockbuster opportunity' with XL102
01/22/21 Piper Sandler
Exelixis combo approval came a month ahead of PDUFA, says Piper Sandler
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
ALNY Alnylam
$147.94 /

+1.4 (+0.96%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
ZTS Zoetis
$155.41 /

-1.14 (-0.73%)

SAGE Sage Therapeutics
$85.02 /

+1.45 (+1.74%)

QTNT Quotient
$4.49 /

-0.06 (-1.32%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

OTRK Ontrak
$59.13 /

-3.3 (-5.29%)

OCUL Ocular Therapeutix
$18.40 /

+0.27 (+1.49%)

GBT Global Blood Therapeutics
$42.60 /

-0.885 (-2.04%)

EXEL Exelixis
$21.70 /

-0.26 (-1.18%)

DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

CHRS Coherus Biosciences
$16.22 /

+0.97 (+6.36%)

CERS Cerus
$6.14 /

-0.325 (-5.03%)

BLFS BioLife Solutions
$39.29 /

+0.07 (+0.18%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

ALNY Alnylam
$147.94 /

+1.4 (+0.96%)

ACAD Acadia
$49.00 /

+1.605 (+3.39%)

  • 03
    Feb
  • 16
    Dec
  • 11
    Nov
  • 14
    Oct
  • 02
    Oct
  • 11
    Sep
  • 12
    Aug
  • 02
    Jul
  • 22
    May
  • 20
    May
ZTS Zoetis
$155.41 /

-1.14 (-0.73%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

ALNY Alnylam
$147.94 /

+1.4 (+0.96%)

SAGE Sage Therapeutics
$85.02 /

+1.45 (+1.74%)

QTNT Quotient
$4.49 /

-0.06 (-1.32%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

OCUL Ocular Therapeutix
$18.40 /

+0.27 (+1.49%)

GBT Global Blood Therapeutics
$42.60 /

-0.885 (-2.04%)

EXEL Exelixis
$21.70 /

-0.26 (-1.18%)

DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

BLFS BioLife Solutions
$39.29 /

+0.07 (+0.18%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

OTRK Ontrak
$59.13 /

-3.3 (-5.29%)

DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

Earnings
Biohaven Pharmaceutical reports Q4 adjusted EPS ($2.69), consensus ($2.97) » 07:32
03/01/21
03/01
07:32
03/01/21
07:32
BHVN

Biohaven Pharmaceutical

$84.92 /

+1.57 (+1.88%)

Reports Q4 revenue…

Reports Q4 revenue $35.1M, consensus $28.23M.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$84.92 /

+1.57 (+1.88%)

BHVN Biohaven Pharmaceutical
$84.92 /

+1.57 (+1.88%)

01/25/21 Piper Sandler
Piper recommends buying Biohaven Pharmaceutical shares at current levels
01/19/21 Canaccord
Biohaven Pharmaceutical price target lowered to $101 from $110 at Canaccord
01/19/21 Mizuho
Biohaven Pharmaceutical price target lowered to $93 from $100 at Mizuho
01/19/21 H.C. Wainwright
Biohaven price target lowered to $111 from $121 at H.C. Wainwright
BHVN Biohaven Pharmaceutical
$84.92 /

+1.57 (+1.88%)

Hot Stocks
Axsome Therapeutics announces 2021 anticipated milestones » 07:04
03/01/21
03/01
07:04
03/01/21
07:04
AXSM

Axsome Therapeutics

$67.52 /

-1.04 (-1.52%)

Anticipated Milestones…

Anticipated Milestones NDA Submissions: AXS-07 for the acute treatment of migraine, submission early 2Q 2021. Clinical Trial Readouts: Phase 2 MERIT trial of AXS-05 in TRD, topline data 2H 2021. Clinical Trial Initiations: Phase 3 trial of AXS-12 in the treatment of narcolepsy 2Q 2021. FDA Meetings: AXS-14 for fibromyalgia 2Q 2021; AXS-05 for smoking cessation 3Q 2021.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
12/15/20 Mizuho
Axsome Therapeutics initiated with a Buy at Mizuho
12/03/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $161 from $131 at Cantor Fitzgerald
AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

Hot Stocks
Axsome Therapeutics expects cash to fund operations into at least 2024 » 07:03
03/01/21
03/01
07:03
03/01/21
07:03
AXSM

Axsome Therapeutics

$67.52 /

-1.04 (-1.52%)

Axsome expects that its…

Axsome expects that its operating expenses will increase year over year in 2021 to support continued pipeline advancement and build-out of the commercial function. Axsome believes that its cash at December 31, 2020, along with the remaining committed capital from the $225 million term loan facility, is sufficient to fund anticipated operations, based on the current operating plan which includes costs for the commercial launch of AXS-05 in MDD and AXS-07 in migraine, into at least 2024.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
12/15/20 Mizuho
Axsome Therapeutics initiated with a Buy at Mizuho
12/03/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $161 from $131 at Cantor Fitzgerald
AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

Earnings
Axsome Therapeutics reports Q4 EPS (78c), consensus (76c) » 07:02
03/01/21
03/01
07:02
03/01/21
07:02
AXSM

Axsome Therapeutics

$67.52 /

-1.04 (-1.52%)

"The focused…

"The focused execution of the Axsome team made 2020 a year of significant accomplishments. We had successful pre-NDA meetings with the FDA for AXS-05 in major depressive disorder and for AXS-07 in migraine, reported positive results from the pivotal ADVANCE-1 trial of AXS-05 in Alzheimer's disease agitation, initiated the second pivotal trial of AXS-05 in this indication, received two new FDA Breakthrough Therapy designations, and built out our commercialization infrastructure," said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. "So far this year, we have submitted to the FDA the NDA for AXS-05 in major depressive disorder, and are nearing submission of the NDA for AXS-07 in the acute treatment of migraine, which is expected early in the second quarter. Our focus for the remainder of the year will be on the regulatory activities surrounding these NDAs, launch readiness to ensure a successful transition to commercialization, assuming product approvals, and continued advancement of the rest of our differentiated late-stage CNS pipeline."

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
12/15/20 Mizuho
Axsome Therapeutics initiated with a Buy at Mizuho
12/03/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $161 from $131 at Cantor Fitzgerald
AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

Hot Stocks
Biohaven's BHV-1200 shows effective neuralization of multiple Covid strains » 07:33
02/22/21
02/22
07:33
02/22/21
07:33
BHVN

Biohaven Pharmaceutical

$82.92 /

+0.68 (+0.83%)

Biohaven Pharmaceutical…

Biohaven Pharmaceutical Holding Company announced that a hyperimmune globulin mimic developed with Biohaven's proprietary MATE platform has demonstrated functional binding and neutralization of the SARS-CoV-2 virus, including the strains known as the "English" and "South African" variants. The preliminary experiments, conducted by Biohaven Labs and an academic collaborator demonstrated that BHV-1200 substantially reduced viral entry into cells. Accelerated development of the COVID-19 MATE program has been supported by the Bill and Melinda Gates Foundation. Vlad Coric M.D., CEO of Biohaven commented, "The battle against COVID-19 -like the virus itself-is dynamic and ever changing. Prophylactic and therapeutic agents with broad specificity against current and future strains will be essential in this ongoing fight to beat the virus. Results from our recent preclinical testing are an exciting advancement for this platform technology, and shows that our lead novel MATE conjugate, BHV-1200, exhibits broad and potent antiviral activity against not only wild type SARS-CoV-2 spike protein but also against mutations of growing clinical relevance, such as those associated with reduced susceptibility to therapeutic monoclonal antibodies and recent SARS-CoV-2 strains." Dr. Coric added, "We believe that BHV-1200 could lead to enhanced efficacy and other benefits over convalescent plasma and alternative antibody-based approaches. Biohaven is excited to advance BHV-1200 into a full clinical development program. We are deeply grateful to the vision and critical funding support provided by The Bill & Melinda Gates Foundation that has accelerated this novel technology towards the clinic."

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$82.92 /

+0.68 (+0.83%)

BHVN Biohaven Pharmaceutical
$82.92 /

+0.68 (+0.83%)

01/25/21 Piper Sandler
Piper recommends buying Biohaven Pharmaceutical shares at current levels
01/19/21 Canaccord
Biohaven Pharmaceutical price target lowered to $101 from $110 at Canaccord
01/19/21 Mizuho
Biohaven Pharmaceutical price target lowered to $93 from $100 at Mizuho
01/19/21 H.C. Wainwright
Biohaven price target lowered to $111 from $121 at H.C. Wainwright
BHVN Biohaven Pharmaceutical
$82.92 /

+0.68 (+0.83%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.